CA
ENDOMETRIUM, ROLE OF ADJUVANT RT/ BRACHYTHERAPY POST SURGERY IN EARLY
ENDOMETRIAL CA
- Creutzberg CL, Nout RA, Lybeert ML, Wárlám-Rodenhuis CC, Jobsen JJ, Mens JW, Lutgens LC, Pras E, van de Poll-Franse LV, van Putten WL, PORTEC Study Group. Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma. International Journal of Radiation Oncology* Biology* Physics. 2011 Nov 15;81(4):e631-
- Nout RA, Smit VT, Putter H, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, van der Steen-Banasik EM, Mens JW, Slot A, Kroese MS, van Bunningen BN. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. The Lancet. 2010 Mar 12;375(9717):816-23.
- Keys HM, Roberts JA, Brunetto VL, Zaino RJ, Spirtos NM, Bloss JD, Pearlman A, Maiman MA, Bell JG. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecologic oncology. 2004 Mar 31;92(3):744-51.
CA ENDOMETRIUM, COMPARISON OF WAI VS CHEMO IN
ADVANCED ENDOMETRIAL CANCERS
- Randall ME, Spirtos NM, Dvoretsky P. Whole abdominal radiotherapy versus combination chemotherapy with doxorubicin and cisplatin in advanced endometrial carcinoma (phase III): Gynecologic Oncology Group Study No. 122. Journal of the National Cancer Institute. Monographs. 1995(19):13-5.
CA ENDOMETRIUM, CHOICE OF CHEMO IN ADVANCED
ENDOMETRIAL CANCERS
- Fleming GF, Brunetto VL, Cella D, Look KY, Reid GC, Munkarah AR, Kline R, Burger RA, Goodman A, Burks RT. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. Journal of Clinical Oncology. 2004 Jun 1;22(11):2159-66.
- DeLeon MC, Ammakkanavar NR, Matei D. Adjuvant therapy for endometrial cancer. Journal of gynecologic oncology. 2014 Apr 1;25(2):136-47.
